- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01526902
Proclear 1-D Multifocal Nondispensing Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Indiana
-
Bloomington,, Indiana, Forente stater, 47405
- Clinical Optics Research Lab, Indiana University,
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Be between 40 and 65 years of age (inclusive)
- Require a reading addition of +1.25 to +2.50D (inclusive)
- Spherical distance CL or spectacle prescription between +3.00D and -5.00D(inclusive)
- Spectacle cylinder less than or equal to 0.75D in both eyes.
- Currently has a reading add correction in their spectacle or CL habitual correction (e.g. if myope, removes distance correction to read)
- Normal binocularity (no amblyopia, no strabismus, no habitually uncorrected anisometropia ≥ 2.00D)
- Have a minimum 2 weeks soft contact lens experience
- Be able to wear the study lens (e.g. good fit is attained and acceptable subjective comfort and vision for the duration of the study)
- Able to read, comprehend and sign an informed consent
- Willing to comply with the wear and study visit schedule
- Monocular best-corrected distance visual acuity ≥ 20/25 in each eye
- No gas permeable contact lens wear for 1 month prior to the study
Exclusion Criteria:
To be eligible for the study, each candidate must not present with any of the following
- Any active corneal infection, injury, inflammation, or ocular abnormality
- Systemic or ocular allergies, which might interfere with contact lens wear
- Systemic disease, which might interfere with contact lens wear
- Ocular disease, which might interfere with contact lens wear
- Pregnant or lactating
- Strabismus/amblyopia
- Habitually uncorrected anisometropia greater than or equal to 2.00 D
- Subjects who have undergone corneal refractive surgery
- Subjects with keratoconus or other severe corneal irregularity contraindicating lens wear
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: omafilcon A / PC 1-D MF
omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF) Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses. |
Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
Andre navn:
Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
Andre navn:
|
Aktiv komparator: lotrafilcon B / Air Optix MF
lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF) Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses. |
Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
Andre navn:
Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Objective Vision Assessments: High Contrast Distance Visual Acuity
Tidsramme: After 1 hour of lens wear
|
Tested with charts distant to the subject with both eyes together in normal lighting conditions.
The unit of measure is logMAR units (logarithm of the minimum angle of resolution) A logMAR acuity of 0.0 equates to 20/20 Snellen acuity.
Positive logMAR values indicate poorer vision and negative values denote better visual acuity than baseline 20/20 value.
|
After 1 hour of lens wear
|
Objective Vision Assessments: High Contrast Intermediate Visual Acuity
Tidsramme: After 1 hour of lens wear
|
Tested with charts at intermediate distance (100cm)distant to the subject with both eyes together in normal lighting conditions.
The unit of measure is logMAR units (logarithm of the minimum angle of resolution) A logMAR acuity of 0.0 equates to 20/20 Snellen acuity.
Positive logMAR values indicate poorer vision and negative values denote better visual acuity than baseline 20/20 value.
|
After 1 hour of lens wear
|
Objective Vision Assessments: High Contrast Near Visual Acuity
Tidsramme: After 1 hour of lens wear
|
Tested with charts set at near point (40cm)distant to the subject with both eyes together in normal lighting conditions.
The unit of measure is logMAR units (logarithm of the minimum angle of resolution) A logMAR acuity of 0.0 equates to 20/20 Snellen acuity.
Positive logMAR values indicate poorer vision and negative values denote better visual acuity than baseline 20/20 value.
|
After 1 hour of lens wear
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Subjective Overall Vision: High Contrast Distance Visual Quality
Tidsramme: After 1 hour of lens wear
|
Subjects instructed to rate Vision quality at distance, intermediate and near vision (OU) using a 0-100 numerical scale where 0 = poor and 100 = excellent.
|
After 1 hour of lens wear
|
Subjective Vision Assessments: High Contrast Intermediate Visual Quality
Tidsramme: After 1 hour of lens wear
|
Subjects instructed to rate Vision quality at distance, intermediate and near vision (OU) using a 0-100 numerical scale where 0 = poor and 100 = excellent.
|
After 1 hour of lens wear
|
Subjective Vision Assessments: High Contrast Near Visual Quality
Tidsramme: After 1 hour of lens wear
|
Subjects instructed to rate Vision quality at distance, intermediate and near vision (OU) using a 0-100 numerical scale where 0 = poor and 100 = excellent.
|
After 1 hour of lens wear
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Peter Kollbaum, OD, PhD, Clinical Optics Research Lab, Indiana University, Bloomington, Indiana, USA
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CV-12-02A
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Presbyopi
-
Bausch & Lomb IncorporatedFullførtMyopi og Hyperopi og presbyopiForente stater
-
Technolas Perfect Vision GmbHUkjent
-
Allotex, Inc.RekrutteringPresbyopiTsjekkia, Irland, Tyrkia, Storbritannia
-
Coopervision, Inc.Centre for Ocular Research & Education, CanadaRekrutteringPresbyopiForente stater, Canada
-
Optall VisionRekruttering
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncFullført
-
Allotex, Inc.AvsluttetPresbyopiBelgia, Irland, Storbritannia
-
Coopervision, Inc.COREFullførtPresbyopiForente stater, Canada
-
Refocus Group, Inc.FullførtPresbyopiForente stater
-
ACE Vision Group, Inc.Avsluttet
Kliniske studier på omafilcon A / PC 1-D MF
-
Coopervision, Inc.Fullført
-
Coopervision, Inc.Fullført
-
Coopervision, Inc.Fullført
-
Coopervision, Inc.Fullført
-
Coopervision, Inc.Fullført
-
Alcon ResearchFullførtBrytningsfeil | Nærsynthet | Hyperopi
-
Brien Holden VisionFullførtBrytningsfeil | PresbyopiAustralia
-
AstraZenecaAcerta Pharma, LLCFullførtBiotilgjengelighet | B-celle lymfoid kreftForente stater
-
University of Wisconsin, MadisonRambam Health Care Campus; University of Pennsylvania; RWTH Aachen University og andre samarbeidspartnereFullførtAnestesibevissthetForente stater, New Zealand, Israel, Belgia, Tyskland, Australia, Nederland
-
Chong Kun Dang PharmaceuticalSeverance HospitalHar ikke rekruttert ennåTidlig pubertetKorea, Republikken